Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823156 | 0.80 | HDAC1 (0.54) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL4585776 | 0.79 | KMT2A (0.45) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL4463800 | 0.79 | ADRB3 (0.44) | — | |
| SCHEMBL3748913 | 0.78 | HDAC1 (0.65) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL1798901 | 0.77 | HDAC1 (0.52) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3695642 | 0.77 | HDAC1 (0.55) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL580233 | 0.77 | HDAC1 (0.55) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL4584170 | 0.77 | HDAC1 (0.46) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL4584322 | 0.77 | L3MBTL1 (0.49) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL30724412 | 0.77 | HDAC1 (0.49) | HDAC1HDAC6HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | HDAC1 2194/4885HDAC6 1316/4885HDAC3 2349/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | HDAC1 864/4885HDAC6 365/4885HDAC3 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.